1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

  • October 2016
  • 75 pages
  • ID: 4523024
  • Format: PDF
  • By Grand View Research

Summary

Table of Contents

The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to a new report by Grand View Research, Inc., HIV continues to be one of the most challenging public health issues worldwide.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.The estimated number of people suffering from HIV in 2015 was recorded to be more than 35 million according to AVERT, a UK-based HIV and AIDS charity.

HIV has vastly affected people from developing and under developed countries, mainly the Asian and African regions. As this infection is not curable at present, the primary aim of antiretroviral therapy is to suppress viral replication in patients usinganti-retroviral agents that are grouped into six different drug classes based on their mechanism of action.

The combination therapy entails medicines from at least two to three drug classes as each class targets different steps in the HIV lifecycle. The combination of drugs is chosen based on patients’ medical history, predisposition to adverse effects of antiretroviral drugs, co-infections with other diseases, and others.


Further Key Findings from the Study Suggest:

NRTIs were the largest class of drugs available in the market in 2015 accounting for over 40% of total drugs available in this vertical

Integrase inhibitors segment is expected to be the fastest growing class of antiretroviral drugs owing to the expected launch of additional integrase inhibitors by major players such as Gilead Sciences, In. and Merck & Co., Inc.

In 2015, North America held the largest market share in 2015 with a share of over 35%. Easier access to diagnostic facilities is one of the key factors supporting sector expansion in this region.

Asia Pacific is projected to be the fastest growing regional segment and will retain its position over the forecast period owing to the enhancing healthcare infrastructure and presence of suitable government initiatives favoring growth

Gilead Sciences, Inc. was the leader in HIV-1 therapeutics sector with respect to market share and drug portfolio, followed byViiV Healthcare in 2015. In addition, in the coming years other small players are expected to enter this sector with their pipeline drugs.

Other important players in this industry include AbbVie, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Boehringer Ingelheim GmbH.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019’; C-C Chemokine Receptor Type 5 (CHEMR13 ...

Glycoprotein 41 (gp41) - Pipeline Review, H2 2019

Glycoprotein 41 (gp41) - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Glycoprotein 41 (gp41) - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Glycoprotein 41 (gp41) - Pipeline Review, H2 2019’; Glycoprotein 41 (gp41) pipeline Target constitutes ...

Retrovirus Tests - Medical Devices Pipeline Assessment, 2019

Retrovirus Tests - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Retrovirus Tests - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Retrovirus Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Retrovirus Tests ...


ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on